Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Wanna Be A Value Investor? Follow Buffett & Play 2 ETF Areas

Published 02/18/2020, 12:00 AM
Updated 07/09/2023, 06:31 AM

Are you an ardent follower of investment guru Warren Buffett? Then you may find his latest bets to be intriguing investment areas.

Normally, Buffett takes interest in companies trading below what he believes is their intrinsic value. He aims long-term outperformance and apparently ignores short-term downturns. Probably this is why this investment veteran is now betting big on two value stocks, biotech giants Biogen (NASDAQ:BIIB) and retailer Kroger (NYSE:KR) . Both the stocks hold a top Value Score of A.

Notably, value investors like good stocks at great prices. The perception is that the lower the P/E or other valuation ratios like PEG or P/B, the higher will be the value of the stock. The logic behind this is that a stock’s current market price does not justify its higher expected earnings or book value and therefore has room to run.

Buffett Bets Big on Biotech Biggie Biogen

In a regulatory filing detailing its U.S.-listed investments as of Dec 31, Buffett’s Berkshire said it took a new 648,000-share stake in drug maker Biogen worth $192.4 million.

Biogen is one of the world’s leading biotechnology companies, which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases. In late January, the company reported fourth-quarter results, wherein it beat on both the lines (read: Can Biotech ETFs Gain on Mixed Q4 Earnings Results?).

The stock beat earnings estimates in the past four quarters, the average being 9.33%. The stock currently has a Zacks Rank #3 (Hold) and belongs to a favorable Zacks industry (placed at the top 28% of 250+ industries).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Biogen has considerable exposure to ETFs like iShares Nasdaq Biotechnology ETF IBB, VanEck Vectors Biotech ETF (LON:BBH) and iShares Evolved U.S. Innovative Healthcare ETF IEIH. IBB and BBH both have a Zacks Rank #2 (Buy) and make these funds a good proxy for Biogen investing. Notably, IBB, BBH and IEIH each has a P/E ratio of about 21x, slightly higher than the SPDR S&P 500 ETF Trust (ASX:SPY) SPY (NYSE:SPY)’s 19.51x.

Retailer Kroger is Buffett’s Another Bet

Berkshire Hathaway (NYSE:BRKa) also took position worth $549.1 million in Kroger Co. It is one of the nation’s largest grocery retailers. Further, it manufactures and processes certain food products that are sold in its supermarkets. The stock comes from a favorable Zacks industry (placed at the top 23% of 250+ industries) but it has a Zacks Rank #4 (Sell).

Kroger has invested heavily to expand online, refurbish stores and improve deliveries to compete with Walmart Inc (NYSE:WMT) and Amazon.com Inc (NASDAQ:AMZN) , per Reuters.

However, Kroger beat earnings expectations in the last two of four quarters, with the average positive surprise of 0.19%. If you are not satisfied with the earnings surprise history, you can bet on the Kroger-heavy ETF. This includes First Trust Nasdaq Retail ETF FTXD. The fund has a P/E ratio of17.77x (read: Retail ETFs Up on Q3 Earnings)..

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Biogen Inc. (BIIB): Free Stock Analysis Report

Amazon.com, Inc. (AMZN): Free Stock Analysis Report

Walmart Inc. (WMT): Free Stock Analysis Report

The Kroger Co. (KR): Free Stock Analysis Report

iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports

VanEck Vectors Biotech ETF (BBH): ETF Research Reports

First Trust NASDAQ Retail ETF (FTXD): ETF Research Reports

First Trust Consumer Staples AlphaDEX ETF (FXG): ETF Research Reports

iShares Evolved U.S. Innovative Healthcare ETF (IEIH): ETF Research Reports

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.